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Abstract                                                                                               
Introduction: Guidelines for primary prevention of sudden cardiac death (SCD) 
advocate implantable cardioverter defibrillator (ICD) therapy in patients with 
reduced left ventricular ejection fraction (LVEF). Many patients are not 
considered for treatment and the net benefit of ICDs in real life is insufficiently 
studied. The aims of these studies were to investigate compliance to guidelines 
and to study the balance between benefits and complications of ICD therapy. 
Methods and Results: Paper I: In a retrospective study of the medical records 
of 187 patients with acute myocardial infarction (AMI), with LVEF ≤35%, we 
evaluated the decision process behind ICD treatment. Inadequate follow-up 
according to guidelines was found in 32% of the patients, while 41% showed an 
improvement in LVEF to such a degree that an ICD was no longer indicated. 
Paper II: A prospective study of 100 patients with AMI and reduced LVEF 
(≤40%). The incidence and time span of improvement of LVEF were studied. At 
one month of follow-up, 55% of the patients had an LVEF of >35%. The mean 
difference in LVEF between one and three months was small (1.9 percentage 
units). A high risk of life-threatening arrhythmias (9%) was found in the first few 
weeks after AMI. Paper III: Using register data, 865 patients with reduced 
LVEF treated with ICDs for primary prevention of SCD were identified. The 
medical records were scrutinized. We found that annually 6% of the patients had 
correctly treated arrhythmias, 2.4% had inappropriate shocks and 4.4% had 
complications requiring reoperation. Men were twice as likely to receive correct 
ICD treatment compared with women. Paper IV: We analyzed intracardiac 
electrograms from 125 explanted ICDs from deceased patients. During the last 
24 h of life, 31% of the patients had received shock treatment. Although 52% of 
the patients had a do-not-resuscitate order, 65% of them still had ICD shock 
therapies activated. 
Conclusions: Follow-up after AMI is insufficient. Most patients show improved 
LVEF after AMI and in the majority the improvement can be confirmed after 
one month, implying that further delay of ICD implantation may not be 
motivated. Patients (especially men) with heart failure benefit from ICD 
treatment, but complications are common and it is crucial to inactivate shock 
treatment towards the end of life. 
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LIST OF ABBREVIATIONS 
AF Atrial fibrillation 
AMI Acute myocardial infarction 
ATP Anti-tachycardia pacing 
CABG Coronary artery bypass graft(ing) 
CI Confidence interval 
CRT Cardiac resynchronization therapy 
CRT-D Cardiac resynchronization therapy in combination with ICD 
DDD Dual chamber pacing, sensing and response 
DDD(R) Dual chamber pacing, sensing, response and rate adaptive 
DNR Do not resuscitate 
ECHO Echocardiography 
EGM (Intracardiac) electrogram 
EOL End of life (battery depletion) 
ICD Implantable cardioverter defibrillator 
LBBB Left bundle branch block 
LV Left ventricular 
LVEF Left ventricular ejection fraction 
NYHA New York Heart Association 
PCI Percutaneous coronary intervention 
SCD Sudden cardiac death 
VF Ventricular fibrillation 
VT Ventricular tachycardia 
VVI Ventricular pacing, sensing and inhibiting 
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1 INTRODUCTION: 
1.1 SUDDEN CARDIAC DEATH:  
Cardiovascular disease is the leading cause of death in Western countries, and in 
Sweden it accounts for 45% of all deaths. Although the overall mortality from 
cardiovascular diseases has declined in recent decades, this does not apply to the 
same degree for sudden cardiac death (SCD). Annually, 8000–10,000 people in 
Sweden suffer from SCD (1). 
A problem with preventing SCD  is the lack of accurate and reliable methods of 
identifying persons at risk (2). Individuals with mild or subclinical heart disease 
account for the majority of sudden deaths, but the likelihood that an individual in 
this group will experience a cardiac arrest over the decades is very low (3).  
Many risk factors have been identified for SCD. One of the most common 
causes of SCD is coronary artery disease (CAD), and about 80% of those who 
develop SCD have CAD. Persons with ventricular arrhythmias are known to be 
at high risk of cardiac arrest, but they represent only a small fraction of all 
victims of SCD. Another major risk factor of SCD is heart failure defined as 
impaired left ventricular function/ejection fraction (LVEF) especially after acute 
myocardial infarction (AMI) (4, 5) (Figure 1). 
  
 2 
Figure 1: Cardiac arrest incidence among persons 50–79 years old in a large, population-
based health maintenance organization in the USA between1986 and 1994. Rea T, 
Pearce RM, Raghunathan TE, Lemaitre RN, Sotoodehnia N, Jouven X, et al. Incidence 
of out-of-hospital cardiac arrest. Am J Cardiol. 2004;93(12):1455-60. 
 
Sudden cardiac death involves a malignant ventricular arrhythmia, which can 
start around scar tissue in the heart, often caused by myocardial infarction. This 
compromised tissue can allow  reentry ventricular tachycardia (VT) or 
ventricular fibrillation (VF). Another more uncommon mechanism behind SCD 
involves VT caused by triggered automaticity. This is seen in rare diseases such 
as long QT and Brugada syndrome. Most of these diseases are genetically 
inherited ion-channel disorders with symptoms presenting early in life. 
Electrical defibrillation of the myocardium is the only practical means of 
terminating ventricular fibrillation. Successful defibrillation is achieved when a 
critical mass of the myocardium is depolarized by establishing a voltage gradient 
throughout the ventricular tissue (3).  
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1.2 IMPLANTABLE CARDIOVERTER AND DEFIBRILLATOR, 
HISTORY 
The implantable cardioverter and defibrillator (ICD) was invented by Dr 
Mieczyslaw Mirowsky, who was born in Poland, and due to his jewish origin, 
escaped to the US and later became director of the Coronary Care Unit at Sinai 
Hospital in Baltimore, Maryland. He was inspired to develop a defibrillator 
when one of his colleagues died suddenly. In the mid-1970s, after several years 
of research, the first defibrillators were implanted in animals. The first human 
implantation was performed in 1980 and five years later the ICD was approved 
for commercial sale by the Food and Drug Administration (6). 
The first ICD implantations required open thoracotomy.  The leads were 
epicardial patches and the device was very large and had to be implanted in the 
abdomen (Figure 2). The device only delivered defibrillation therapy and pacing 
support function was not added until the 1990s. Initially, the complex 
implantation procedure required postoperative hospitalization of approximately 
one week and the device only had a longevity of less than two years (7). 
1.3 ICD FUNCTIONS 
Modern ICDs are much smaller, the leads are transvenous and implantation is 
faster, safer and less complicated (Figure 3). All ICDs are now equipped with 
regular pacemaker functions as well as the ability to recognize and attend to life-
threatening ventricular arrhythmias. If VT or VF is detected, the ICD can convert 
the arrhythmia to sinus rhythm by either delivering high-voltage shocks (500–
700 volts) or by carefully timed pacing impulses at a rate faster than the VT, so-
called antitachycardia pacing (ATP). ATP is painless and converts 90% of all 
VTs, but there is 1–3% risk of acceleration of the arrhythmia (3). The devices 
have a memory function so that information regarding the morphology and rate 
of the arrhythmia is stored, as well as information regarding electrocardiographic 
signals before, during and after therapy.  
ICD systems are implanted transvenously under local anesthesia. The surgery 
takes approximately 60 minutes. In many places acute defibrillation testing, after 
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implantation, is performed by inducing VF and letting the device deliver a shock 
to ensure a safety margin for treatment of spontaneous arrhythmias. Since 
defibrillator testing involves inducing potentially fatal arrhythmias it is not 
without risk, and today there is a growing preference not to test the defibrillation 
threshold (8, 9). 
Figure 2. The first ICD. “Materials "[Image] provided courtesy of Boston Scientific. © 
2014 Boston Scientific Corporation or its affiliates. All rights reserved." 
 
 
  
 
4 
implant tion, is performed by inducing VF and letting the device deliver a shock 
to ens re a safety margin for treatment of spontaneous arrhythmias. Since 
defibrillator testing involves inducing potentially fatal arrhythmias it is not 
without risk, and today there is a growing preference not to test the defibrillation 
threshold (8, 9). 
Figure 2. The first ICD. “Materials "[Image] provided courtesy of Boston Scientific. © 
2014 Boston Scientific Corporation or its affiliates. All rights reserved." 
 
 
  
 5 
 
Figure 3. The first ICDs and the evolvement. “Materials "[Image] provided courtesy of 
Boston Scientific. © 2014 Boston Scientific Corporation or its affiliates. All rights 
reserved." 
 
In order to deliver a high-voltage shock to the heart, a special type of lead is 
required which has one or two special coils of wire capable of delivering the 
high energy. It is important that the lead can pace and sense even small intrinsic 
signals. In particular, VF is often characterized by low amplitude ventricular 
signals that must be interpreted correctly, and at the same time it is important 
that the device does not oversense T-waves, noise or far-field signals (3). 
Modern ICDs are made of titanium and often have lithium-vanadium batteries. 
The devices can deliver shock therapy of 2–42 J by way of store and charge 
capacitors, and the longevity is 6–8 years. 
There are several types of ICD system. Single-chamber ICDs have only a high-
voltage lead and in addition to defibrillation can allow VVI(R) pacing. Dual-
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chamber ICDs are today more common than single-chamber devices. In addition 
to the defibrillator lead they have an atrial lead which enables DDD(R) pacing 
and this may improve the discrimination between atrial and ventricular 
tachycardia. ICDs can also be combined with cardiac resynchronization therapy 
(CRT) to improve left ventricular function among patients with broad QRS and 
congestive heart failure (10). 
1.4 CARDIAC RESYNCHRONIZATION THERAPY (CRT) 
Heart failure is often associated with disordered electrical timing, which can 
cause heterogeneous and delayed ventricular activation. Delayed ventricular 
electric activation is manifest by prolonged QRS duration, usually in the form of 
a left bundle branch block (LBBB). 
Prolonged atrioventricular delay may result in atrial contraction before venous 
return is completed, and early mitral valve closure which can diminish 
ventricular volume and cause mitral regurgitation.  
Optimal inter- and intraventricular coupling is important for maximal ventricular 
pumping function. Interventricular delay refers to the coordination between the 
right and left ventricle, whereas intraventricular delay refers to the coordination 
between the septum and lateral wall in the left ventricle (7). By placing an 
electrode in a vein, outside the left lateral wall, in combination with the ordinary 
leads, CRT works by partially or wholly correcting the atrioventricular, 
interventricular and most importantly the intraventricular dyssynchronies (11). A 
meta-analysis of four large CRT studies covering more than 5300 patients 
showed that CRT was effective in reducing both mortality and hospitalization 
(12). 
1.5 INDICATIONS FOR AN ICD 
Initially, ICDs were solely recommended as secondary prevention for survivors 
of cardiac arrest or previously documented life-threatening arrhythmia unrelated 
to a transient or reversible cause.  
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In recent years, implantation of primary preventive ICDs among patients at high 
risk of SCD has become frequent. 
The term “primary prevention” is used to describe the use of ICD therapy in 
individuals at risk of SCD but without a history of sustained ventricular 
arrhythmias.  
For primary prevention of SCD, current guidelines in both Europe and the USA 
recommend ICD implantation for patients with previous AMI (≥40 days post 
MI) who have LVEF ≤35% and NYHA class II–III, or LVEF ≤30% and NYHA 
class I. An ICD is also recommended in patients with non-sustained and 
inducible VT and LVEF ≤40% and in non-ischemic patients with LVEF ≤35%. 
It is recommended to wait three months before ICD implantation after 
revascularization (13, 14). According to guidelines, patients have to be on 
optimal medical therapy and in good functional status with respect to their non-
cardiac comorbid situation before implantation (14). A contraindication to ICD 
treatment is expected survival of less than one year. 
Updated guidelines from the Swedish National Board of Health recommend 
implantation of primary preventive ICDs in patients with LVEF ≤35% and 
NYHA class II–III regardless of etiology and ≥40 days after AMI. Recently, 
primary preventive ICDs were recommended first three months after AMI (1). 
It is also advisable to implant a primary preventive ICD in patients with familial 
conditions with a high risk of SCD, for example Brugada syndrome, long QT 
syndrome or severe hypertrophic cardiomyopathy.  
According to both European and American guidelines, CRT or CRT-D can be 
recommended for patients with LBBB, QRS duration ≥120 ms, EF ≤35% and 
NYHA class II–III and can be considered in patients with non-LBBB who have 
QRS duration ≥150 ms (13). If NYHA class IV patients are stable, CRT without 
an ICD is recommended. 
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1.6 FREQUENCY OF ICD IMPLANTATION 
ICD treatment, especially for primary prevention, is becoming more common. It 
is used worldwide and the number of implantations has grown exponentially in 
almost every surveyed country since 2005 (Figure 4). In 2007 the average 
implantation rate in western European countries was 155 per million inhabitants 
(15). The USA remains clearly the world’s largest implanting country, with 
133 262 ICD implants, or 434 new implants per million inhabitants in 2009 (16). 
In Sweden the rate of ICD implantations increased from 74 per million 
inhabitants  in 2007 to 136 per million in 2012, but compared with other western 
European countries Sweden still has a low implantation rate (Figure 5) (15, 17). 
The reason for this is not clear, but it may be due to economic concerns, fear of 
adverse effects, inadequate follow-up after AMI, or lack of identification of 
patients that will benefit from the treatment. 
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Figure 4. ICD implantation rates 2005 and 2012 in Europe (Source population data: 
Eurostat Units - Eucomed based on reports from major manufacturers* Europe 
represents total of listed countries (N/A countries excluded).  
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 Figure 5. ICD, CRT-D and CRT-P implantation rates 2012 (Source population data: 
Eurostat Units - Eucomed based on reports from major manufacturers* Europe 
represents total of listed countries (N/A countries excluded)  
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1.7 STUDIES OF ICD EFFICACY  
A large number of randomized trials illustrating the efficacy of ICD therapy have 
been published. The first studies were performed in high-risk patients with 
aborted cardiac arrest or poorly tolerated VT. ICDs were compared with best 
medical therapy and the results demonstrated a large survival benefit in the ICD 
groups (18).  The MADIT and MUST studies were the first primary preventive 
ICD trials. They included patients with heart failure after AMI and non-sustained 
VT; thus patients at a high risk of SCD. The results showed a large absolute risk 
reduction with ICD treatment, of more than 25% (19, 20).  
At the beginning of the 21st century a large number of studies performed in 
patients with lower risks of SCD were published. The MADIT II study included 
patients with LVEF ≤30% and remote AMI (21). In the SCD-HeFT study both 
patients with ischemic and non-ischemic etiologies of heart failure were included 
(22) and in the DEFINITE trial , patients with only non-ischemic etiology and 
reduced LVEF were randomized to ICD or best medical therapy (23). Pooled 
analyses of these and other primary preventive studies have provided strong 
evidence for the beneficial effect of ICD therapy and an approximately 8% 
absolute risk reduction of all-cause mortality regardless of etiology (24, 25). 
There are few studies designed to compare CRT in combination with ICD (CRT-
D) with CRT only. A systematic analysis performed to compare the efficacy of 
these devices showed no reduction in all-cause mortality in the CRT-D group 
compared with the CRT group during the first year after implantation. However, 
after one year of follow-up there was a reduction in mortality in the CRT-D 
group (26). The result of this analysis is uncertain, however, as apart from the 
Companion study (27), all other included studies in the analysis were non-
randomized and heterogeneous in demographic factors.  
In contrast to the few studies carried out to compare CRT with CRT-D therapy, 
there are several recently published studies (RAFT, REVERSE, MADIT-CRT 
trial) in which ICD and CRT-D treatment have been compared. In summary, it 
seems beneficial to use CRT-D rather than ICD treatment in patients with 
broader QRS (≥150 ms) who are in NYHA class II or III (28-32). 
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1.8 TIMING OF ICD IMPLANTATION 
Although the risk of SCD is highest in the first month after AMI (33, 34), there 
is no benefit in having ICD treatment early after myocardial infarction. In both 
the DINAMIT and the IRIS study patients with moderately reduced LVEF a few 
days after AMI were randomized to ICD or medical therapy (33, 35). Although 
the risk of SCD was reduced in the ICD groups there were no differences in all-
cause mortality. There are a number of reasons why these two trials failed to 
show improved survival. It is possible that patients shortly after AMI suffer from 
re-infarction, worsened heart failure or other causes of death. Another 
explanation could be that many patients recover their left ventricular function 
after AMI (36). 
International guidelines advocate primary preventive ICDs for patients with 
reduced LVEF more than 40 days after AMI or after three months in cases of 
revascularization, but the optimal timing has never been evaluated in prospective 
studies. 
Post hoc analyses of the SCD-HeFT study imply that time since AMI does not 
modify the effect of ICD treatment as regards all-cause mortality (37), but other 
studies indicate that the risk of ventricular arrhythmias increases with time 
elapsed from revascularization (38). A recently published meta-analysis of nine 
primary preventive ICD trials revealed no evidence that the efficacy of primary 
prevention ICD therapy depends on time to implantation from 40 days or more 
after AMI (39).  However, delayed decisions regarding ICD therapy after AMI 
are associated with a lower likelihood of implantation (40).  
1.9 SELECTION OF PATIENTS FOR PRIMARY PREVENTIVE ICDS 
At the moment, the guidelines for implantation of primary preventive ICDs are 
based on LVEF and NYHA class, but there is no evidence that this is the best 
method to identify patients who will benefit the most from ICD therapy (41). In 
one study, many patients with LVEF ≤35% did not had ICD therapy during 5 
years of follow-up (22), and ICD treatment is costly and may cause 
complications.  
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One problem is that factors associated with an increased risk of SCD are also 
associated with increased all-cause mortality. For instance, patients receiving 
dialysis have a high risk of SCD, but cardiovascular mortality remains high even 
if they receive defibrillators (42). However, the results of a recently published 
meta-analysis imply that although mortality is high in patients with impaired 
renal function, ICDs still reduce mortality (43). Another example is advanced 
age. The incidence of SCD increases with age, but data regarding ICD efficacy 
in older age groups is limited and divergent, particularly as regards patients of 75 
years of age or more. However the results of a meta-analysis suggest 
that primary prevention ICDs in older patients may be beneficial (44). 
Another question is if women benefit equally from primary preventive ICDs 
compared with men. A meta-analysis of five trials with a total of 934 female 
patients failed to show a reduction in all-cause mortality (45), raising the 
question of whether indications for ICD treatment should be different for women 
than for men. On the other hand, women seem to benefit more from CRT 
therapy. In the MADIT-CRT trial, women showed significant reductions in 
death and heart failure, and consistent echocardiographic evidence of reverse 
cardiac remodelling (46). 
Many earlier studies have been carried out in an attempt to identify risk factors 
that could help pinpoint patient subgroups expected to gain the most benefit from 
ICD therapy. In the VALIANT trial >11 000 patients with AMI were included. 
In the short term the risk of SCD was increased among patients with higher heart 
rate and impaired renal function, but in the long term a reduced LVEF was a 
stronger predictor of SCD (47).  
 Retrospective post hoc analyses of patients enrolled in the MADIT-II study (48) 
showed that age >70 years, a history of atrial fibrillation (AF), renal failure, 
affected ventricular depolarization and advanced heart failure (NYHA class III–
IV class) were significantly associated with prognosis in a J-shaped relationship. 
Patients without risk factors and patients at a very high risk showed no benefit 
from ICD therapy, while medium-score patients treated with an ICD 
demonstrated a large reduction in the risk of death. These findings were also 
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reproduced in two American registry-based studies (49, 50). A meta-analysis 
carried out to identify factors associated with mortality in patients with heart 
failure treated with ICDs was published recently. In addition to earlier-identified 
risk factors, patients with chronic obstructive pulmonary disease, diabetes, 
peripheral vascular disease and appropriate and inappropriate ICD shocks had a 
higher mortality rate (51). Similar results were found in a prospective study in 
the USA, where poor functional status, low mean arterial pressure, diabetes, low 
BMI and AF were strongly associated with death within a year in spite of ICD 
treatment (52). In summary, these studies imply that the net benefit ICDs 
decreases in patients with increased morbidity because death occurs as a result of 
causes other than lethal arrhythmia.  
1.10 COMPLICATIONS  
Controversy exists concerning the cost-efficacy of ICDs for primary prevention 
in patients with heart failure, partly because of the relatively high rates of post-
implantation hospitalization and device-related complications (53, 54).  
The reported complication rates associated with ICD treatment vary in different 
studies from 1.8 to 31% (55-57). Complication rates in real-life surveys are 
much higher than in randomized studies, which could be due to different 
selection of patients and the time-span of follow-up. There are also problems 
with early failure of small calibre defibrillator leads, and lead problems increase 
with time (58). Both primary CRT-D implantations and upgrade procedures are 
associated with more complications than primary ICD implantation, and an 
increased risk of complications is associated with device replacement (59).  
Another issue is device-related infections. Multiple studies confirm increasing 
infection rates and the fact that the risk of infections increases with both time 
since primary implantation and the number of surgical procedures, and this may 
eventually have an impact on mortality (60-62).  
There are also deaths associated with incorrect deactivation of defibrillators (63) 
and the true incidence of ICD malfunction is not known as a result of an absence 
of systematic post-mortem assessment of these devices (63, 64). Only a few 
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devices are sent in and interrogated after death, despite the fact that the Heart 
Rhythm Society emphasizes the importance of returning explanted devices to 
manufacturers for analysis (64). Implantable cardioverter-defibrillators are 
supposed to protect patients from SCD, but several studies have shown that only 
60% of potentially fatal arrhythmias can be terminated (25). Data analysis of 
ICDs from deceased patients could help us to understand the mechanisms behind 
SCD in patients with ICDs and perhaps optimize the programming of the 
devices.  
1.11 SHOCK TREATMENT 
ICD shock treatment can be lifesaving but it can also cause great pain and 
anxiety. Patients who receive shocks experience a worse quality of life (65-67). 
There are also studies that imply that shock therapy, both appropriate and 
inappropriate, is associated with higher mortality (68), but perhaps only in 
patients with ischemic cardiomyopathy and during the first four years after 
device implantation (69). There is also a risk that an ICD is not always able to 
stop ventricular arrhythmias. How common arrhythmias are at the end of life and 
the incidence of shock therapy is unknown . There is a possibility that terminally 
ill patients develop conditions such as hypoxia, electrolyte disturbances, stroke 
and heart failure, all with an increased risk of triggering arrhythmias and thereby 
increasing the risk of shock and an unnecessarily painful death. 
The frequency of inappropriate shocks varies in different studies (70), but there 
are ways to minimize the number of unnecessary shocks. More “conservative” 
programming (i.e. higher VT zones with longer detection intervals and more 
ATP therapies before shock therapy) may contribute to reducing the number of 
unnecessary shocks (71, 72). 
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2 AIMS 
• To investigate compliance to guidelines regarding implantation of a 
primary preventive ICD. 
• To examine the extent and timing of improvement in left ventricular 
function after AMI, in order to rapidly identify candidates appropriate for 
ICD therapy for primary prevention. 
• To evaluate the net benefit of ICD treatment in patients with heart failure 
with regard to the incidence of appropriate and inappropriate ICD 
therapies, complications and possible gender differences.  
• To investigate the occurrence of arrhythmias and shocks in ICD-treated 
patients at the end of life. 
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3 MATERIAL AND METHODS 
Study I 
We carried out a retrospective study of medical records from AMI patients 
admitted to Södersjukhuset and Danderyd University Hospital between January 
2008 and December 2009. Patients with an LVEF of ≤35% and age ≤80 years at 
the time of admission were included. Evaluation of follow-up and 
echocardiographic recordings 1–3 months after AMI was performed. We 
reviewed indications and contraindications as regards primary prevention ICDs 
and whether or not the responsible physician made a decision concerning ICD 
treatment. We also evaluated mortality and the causes of death, based on medical 
records, death certificates and autopsy reports when available.  
Contraindications regarding ICD treatment were assessed by two independent 
reviewers from different hospitals. In cases of conflicting opinions, consensus 
was reached by way of mutual decision. Contraindications to ICD therapy were 
defined as dementia, severe mental illness, current alcohol or drug abuse, NYHA 
Class IV or expected survival <1 year because of underlying morbidity. In 
patients with repeated echocardiography (ECHO), we evaluated the proportion 
of patients with LV function improved to such a degree that an indication for an 
ICD was no longer present.  
Echocardiographic recordings at discharge and at follow-up were assessed with 
respect to LVEF. We considered the follow-up as inadequate in patients with 
impaired LV function and no contraindications to ICD treatment, if follow-up 
ECHO was not performed in 1–3 months, and/or the physician did not discuss 
ICD treatment. 
The patients that had received inadequate follow-up according to guidelines were 
offered a new follow-up with ECHO and a decision on treatment with an ICD if 
appropriate. 
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Study II 
A prospective study of 100 AMI patients admitted to Danderyds University 
Hospital or Södersjukhuset with heart failure defined as LVEF ≤40%. The main 
exclusion criterion was a short life expectancy. Patients that fulfilled the 
inclusion criteria and accepted participation in the study were included. 
Dobutamine stress ECHO was performed on day 3–8 after myocardial infarction 
and this was followed by serial ECHO examinations after 1, 3, 6 and 12 months. 
The patients’ morbidity, medication, ECG, angiography findings and NYHA 
classes were recorded. Blood sample were collected and the patients underwent 
Holter registration.  
The paper based on this study was focused on the ECHO results 3–8 days, one 
month and three months the AMI. 
Study III  
Using Swedish national ICD registry data, 865 consecutive patients receiving an 
ICD for primary prevention during 2006–2011 were identified at four tertiary 
care hospitals in Stockholm and Lund. All patients who had primary preventive 
ICDs implanted due to heart failure (defined as LVEF ≤35%) were included. We 
excluded patients with a history of previous sustained ventricular arrhythmias, 
cardiac arrest, Brugada and long QT syndromes, arrhythmogenic right 
ventricular dysplasia and hypertrophic cardiomyopathy. 
The medical records of all 865 patients were scrutinized in order to assess the 
presence of appropriate and inappropriate therapies, complications and mortality. 
The data was cross-validated regarding survival status using the national 
Swedish Cause of Death Registry 
Data was extracted regarding clinically relevant risk factors known at the time of 
ICD implantation. The patients were assign to one of three risk factor groups and 
we investigated if the groups differed as regards mortality and appropriate 
therapy. The risk factors used were NYHA class >II, age >70 years, kidney 
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diseases defined by blood urea nitrogen ≥50 mg/dl and/or serum creatinine ≥2.5 
mg/dl, QRS duration ≥120 ms, atrial fibrillation and diabetes. 
The paper based on this study was focused on the results of analyses of 
appropriate and inappropriate therapies, complications, mortality and gender 
differences.  
Study IV 
We prospectively studied 130 ICD devices explanted after death from 26 
participating hospitals. The study population’s demographic data, time and cause 
of death were obtained from patients’ medical records, the Swedish ICD and 
Pacemaker register, the National Board of Health and Welfare and death 
certificates from the Swedish Tax Agency. All the ICDs were interrogated and 
all available intracardiac electrograms (EGMs) from the last 24 h before death 
were retrieved. 
Three investigators, two of them blinded to the patients’ medical records and 
arrhythmic histories performed the review and analysis of the EGMs 
independently. If the investigators disagreed on the origin of the arrhythmia, i.e. 
ventricular or supraventricular, a fourth blinded investigator proceeded with the 
analysis and a consensus decision was taken.  
The incidence of ventricular tachyarrhythmia and shock treatment was recorded. 
Shocks were classified as appropriate or inappropriate. In addition to the 
occurrence of any shocks, we assessed the number of shocks received during the 
last 24 hours of life.  
We also investigated the cause of death, whether the death occurred at hospital 
and if there was a Do-Not-Resuscitate order. 
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4 STATISTICAL ANALYSES 
Continuous data are presented as mean ± standard deviation or median [IQ 
range] as appropriate and nominal data as percentage (number of cases). 
Fischer’s exact test was used for comparison between categorical variables and 
Student’s t-test for comparison of continuous variables. If the parameters were 
normally distributed, confidence intervals (CIs) were calculated, and in cases 
where we did not assume a normal distribution Wilcoxon’s Signed Rank Test 
was used. Analysis of variance (ANOVA) was used when comparing more than 
two groups.  A two-sided p-value < 0.05 was considered statistically significant. 
For survival analysis we used Kaplan–Meier curves, with log-rank testing. Cox 
regression analysis was used for evaluation of independent predictors of survival 
and event-free survival. All variables with a p-value <0.20 in univariate analysis 
were entered into multivariate backwards stepwise regression analysis. 
Assessment of intra-observer variability as regards LVEF was performed by 
calculating LVEF twice during the same examination on two different occasions 
without knowing the previous result. Similarly, assessment of inter-observer 
variability for LVEF estimations was performed without any knowledge of the 
result from the other researcher. Variability was calculated as the mean 
percentage error expressed as the absolute difference between two sets of 
observations divided by the mean of the observations. All analyses were carried 
out with SPSS software (IBM, Version 21). In Paper II we assumed a 20% 
dropout rate and we calculated that enrollment of 100 patients would provide 
80% power to detect a difference of at least 10 percentage units in LVEF. 
Ethics 
All studies were approved by the local ethics committee and were performed in 
accordance with the Declaration of Helsinki. 
DNR: 2010/882-31/2; 2012/771; 2008/1527–31/4 
The patients in Study II gave written informed consent. 
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5 RESULTS 
5.1 STUDY I: 
Acute myocardial infarction was diagnosed in 3372 patients during the pre-
defined period. Of these, 2023 (60%) patients were of age ≤80 years, and 187 
(9.2%) had an EF of ≤35%.  
Baseline charactersitics are presented in Table 1. Most patients with AMI and 
LV dysfunction received a follow-up visit after the myocardial infarction, but 
inadequate follow-up according to guidelines was found in 32%, mainly because 
of lack of an ECHO examination in time, and in some cases ICD treatment was 
not considered. An ICD for primary prevention was implanted in 13% of the 
patients and the median time to implantation was 6.6 months. Contraindications 
for ICD implantation were found in 28% of the patients (Figure 6). Many 
patients (41%) showed improvement in LV function to such a degree that ICD 
treatment was no longer indicated. The mortality rate was high (9%) and a few 
of those who died might have been saved by ICD treatment (Figure 7). 
The main results of this study demonstrate that follow-up after AMI is 
insufficient and may increase the risk of SCD. Another finding is that the 
number of patients who develop low LVEF (≤35%) after AMI is small, and a 
significant proportion of patients experience improvements in LV function, 
making primary preventive ICD treatment redundant. 
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Table 1. Characteristics of patients with ejection fraction ≤35%, and age <80 years. 
Characteristics 
Patients 
n= 187 (%) 
Age, years (±SD) 67.5 ± 9 
Male/female 137 (73)/50 (27) 
Diabetes mellitus 62 (33) 
Hypertension 91 (49) 
History of congestive heart failure 55 (29) 
Prior coronary artery bypass graft surgery 43 (23) 
Prior myocardial infarction 71 (38) 
Angina pectoris 58 (31) 
Atrial fibrillation 52 (28) 
Baseline EF, % (±SD) 29 ± 6 
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Figure 6. Patients with acute myocardial infarction in 2008–2009 discharged from 
Södersjukhuset or Danderyds sjukhus. 
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Figure 6. Patients with acute myocardial infarction in 2008–2009 discharged from 
Södersjukhuset or Danderyds sjukhus. 
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Figure 7. Cause of death. 
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Figure 7. Cause of death. 
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5.2 STUDY II 
Out of the 100 patients included originally, nine were excluded before the first 
ECHO due to complications after AMI or inadequate quality of the 
echcardiographic examinations. Baseline data are based on the remaining 91 
patients. In addition, five patients did not undergo all the ECHOs because of 
fatigue or coronary artery bypass grafting (CABG). 
The study population mostly consisted of men (78%), with a mean age of 68 
years and 71% without previously known cardiac disease. Mean and median EF 
at inclusion was 31% [17.5–40] (Table 2). Most patients (59%) had stenosis in 
the left anterior descending artery and 86% of all patients were treated by means 
of percutaneous coronary intervention (PCI). All patients except one were started 
on beta-blockers and ACE inhibitors or angiotensin II receptor antagonists. 
At one month of follow-up, more than half (55%) of the patients had improved 
to such an extent that there was no longer a clear indication for ICD treatment. 
The mean improvement in LVEF between inclusion and one month was 6.5±9 
percentage units (p<0.001). Only four of the 38 patients with LVEF <35% at one 
month improved further and no longer met the ICD criterion (LVEF range 38–
48%) after three months. The mean difference in LVEF between one and three 
months was small but significant, 1.9 percentage units (Figure 8). 
 During the first weeks of follow-up 9% (n=8) of the patients suffered from life-
threatening arrhythmia requiring resuscitation. These patients survived and had 
an ICD implanted. Two other patients succumbed to non-sudden cardiac death. 
The patients that developed life-threatening ventricular arrhythmias did not differ 
significantly from the other patients in baseline characteristics nor in LVEF at 
inclusion. Patients who did not show improved LVEF were more likely to have 
heart failure and low LVEF at inclusion. 
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Table 2. Left ventricular ejection fraction and end-diastolic diameter following acute 
myocardial infarction. 
§ ECHO = Echocardiography, * AMI = Acute Myocardial Infarction, † LVEF = Left 
Ventricular Ejection Fraction, ‡ LV = Left Ventricular  
ECHO § Definition Time 
after 
AMI* 
LVEF† 
(%, 
mean±SD) 
LV ‡ end-
diastolic 
diameter 
(cm) 
p-value for 
difference in 
LVEF vs. 
ECHO 1 
ECHO 1 Clinical ECHO, 
determining 
inclusion 
2.1±1.3 
days 
31±5.8 5.2±0.7  
ECHO 2 First study 
ECHO, before 
discharge 
5.0±2.3 
days 
32±7.0 5.4±0.8 p=0.005 
ECHO 3 Second study 
ECHO 
1 month 38±11 5.4±0.8 p<0.001 
ECHO 4 Third study 
ECHO  
3 months 40±11 5.3±0.6 p<0.001 
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Figure 8a. Left ventricular ejection fraction at inclusion, one month and three months 
after AMI among the patients who met the criterion for ICD treatment after three 
months (n=35). 
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Figure 8b. Left ventricular ejection fraction at inclusion, one month and three months 
after AMI among the patients who did not meet the criterion for ICD treatment after 
three months (n=51). 
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5.3 STUDY III 
Out of the 865 consecutively included patients with primary preventive 
defibrillators, 82% were male, the mean age was 64±11 years, 62% had ischemic 
etiology behind heart failure and mean LVEF at inclusion was 26±11%. The 
baseline characteristics of the patients in our cohort were compared with those in 
patients in three major randomized prospective clinical trials (COMPANION, 
DEFINITE and MADIT II studies) (27, 73, 74) and overall the only important 
differences were higher prevalences of atrial fibrillation and beta-blocker 
treatment, and longer follow-up (three years). 
The annual rate of appropriate ATP and/or shock treatment because of 
ventricular arrhythmias was 6%. Men were more than twice as likely to receive 
ICD treatment compared with women (p=0.02; Figure 9). Complications were 
common. The annual rates of inappropriate shocks and complications requiring 
reoperation were 2.4% and 4.4% respectively. The most common problem 
requiring reoperation was dislocation or dysfunction of the ICD electrode or the 
LV electrode, which together accounted for 60% of all the complications. 
Infections accounted for 13% of the complications and all these patients had to 
have their entire device systems removed. Very few patients had per-operative 
complications such as perforation or pneumothorax (Table 3). The time between 
primary implantation and reoperation varied widely, the median time being 10 
months [range 0–67 months]. There was no gender difference in complication 
rates.  
The annual mortality rate was 8.4%, and among those who died, 21% had 
previously suffered ventricular arrhythmia correctly treated by means of ATP or 
shock. In patients who received appropriate treatment and later died, the median 
time from first correctly treated arrhythmia to time of death was 16 months 
[range 0.2–47 months]. The most common cause of death was heart failure 
(40%) and 4% died as a result of intractable ventricular arrhythmia (Figure 10). 
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Figure 9. Percentages of male and female patients receiving appropriate therapy, 
inappropriate shocks, complications requiring reoperation, or death during 35 months of 
follow-up. 
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Table 3. Device-related complications 
Type of complication Frequency Percentage
Peroperative complications 
Pneumothorax 3 0.3
Perforation 2 0.2
Other 4 0.5
Postoperative complications 
ICD electrode dysfunction 36 4.2
LV electrode dysfunction 31 3.6
Atrial electrode dysfunction 12 1.4
Pocket-related problems 3 0.3
Infection 15 1.7
Multiple 7 0.8
Inappropriate shocks 61 7
Other 3 0.3
Total 177 20.4
 
  
 Type of complication Number (%) 
Perioperative complications  
Pneumothorax 3 (0.3%) 
Perforation 2 (2.0%)  
Other 4 (0.5%) 
Postoperative complications  
ICD-electrode dysfunction 36 (4.2%) 
LV-electrode dysfunction 31 (3.6%) 
Atrial-electrode dysfunction 12 (1.4%) 
Pocket-related problems 3 (0.3%) 
Infection 15 (1.7%) 
Multiple 7 (0.8%) 
Inappropriate shocks 61 (7.0%) 
Other 3 (0.3%) 
Total 177 (20.4%) 
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Figure 10. Cause of death 
  
In the same cohort the 865 ICD patients were evaluated as regards morbidity 
before implantation. In 790 patients there was enough data, and these patients 
were assigned to one of three risk-factor groups. The average number of risk 
factors was 2.2±1.3, and in 7% no risk factors (low risk) were identified, 54% 
had 1–2 risk factors (medium risk) and 39% had 3–5 risk factors (high risk). The 
patients in the high-risk factor group generally had more co-morbidity in 
addition to the conditions included in the risk score, compared with those in the 
low- and intermediate-risk groups. There was no significant difference in 
survival between the low- and medium-risk groups, but a significant increase in 
mortality in the high-risk group. Neither appropriate nor inappropriate therapy 
differed significantly between groups. 
 Since diabetes was an independent predictor of both death and “death or 
appropriate ICD therapy”, a new risk score was constructed, incorporating 
diabetes. Multivariate analysis was repeated, showing a highly significant 
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independent predictive value for all-cause mortality using the new risk-group 
variable, but no differences in appropriate therapy (Figure 11).  
In conclusion, the results of this study show that ventricular arrhythmias 
necessitating ICD therapy are common (6% annually). Women are less likely to 
have correct ICD treatment, but have the same degree of treatment 
complications, thus reducing the net benefit of their treatment. Despite 
considerable mortality associated with a high-risk score, similar ICD-discharge 
rates across all three risk factor groups was demonstrated suggesting similar 
SCD prevention benefit. 
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Figure 11. Kaplan–Meier curves for all-cause mortality, using the proposed new risk-
score system including diabetes. 
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5.4 STUDY IV 
Devices from 130 ICD patients who died between 2003–2010 were collected. 
Due to battery depletion after death, five of the devices were excluded, and 
descriptive data was based on the remaining 125. The most common indication 
for implantation was secondary prevention of SCD (82%) and 35% had CRT-D. 
Most of the patients (80%) were in hospital or a care facility at the time of death. 
More than half (52%) of the 125 patients had a Do-Not-Resuscitate (DNR) order 
that was active in their medical records. 
Ventricular arrhythmias were common. In the last 24 hours of life 38 patients 
had VT or VF and in the last hour 33 patients had ventricular arrhythmias  
(Figure 12). Among the 97 patients with shock treatment programmed on, there 
were 31 who experienced shock treatment during the last 24 hours of life. Of 
these, 45% had 1–2 shocks, 23% had 3–10 shocks and 32% had more than 10 
shocks.  Inappropriate therapy was given to 4 patients as a result of 
supraventricular tachycardia or oversensing. In 39% of the patients receiving 
shock treatment in the last 24 h, there was evidence suggesting that the patient 
had recognized that shock therapy was given by showing signs of pain or stress.  
Among the 65 patients with a DNR order, 65% of them still had ICD shock 
treatment on and 10 patients had shock treatment. One of them received 42 
shocks during the last hour in life. 
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Figure 12. Inclusion, exclusion, arrhythmia detection and shock therapy given at 24 
hours and 1 hour before death. *Change in programming during the last 24 hours. 
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The most common cause of death was heart failure (37%). Arrhythmic death was 
the primary cause of death in 13% and in 3% of cases the patient’s death could 
have been system-related, caused by possible device malfunction (undersensed 
VF, or lead failure with death caused by bradycardia).  
The main finding in this study was that ventricular tachyarrhythmias are 
common during the last 24 hours of life, and almost one third of the ICD patients 
(31%) had shock therapy. In spite of a Do-Not-Resuscitate order many patients 
still had shock therapy turned on. 
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6 DISCUSSION 
Low ICD implantation rates in Sweden 
Compared with other  countries in the Western hemisphere, Sweden has a low 
ICD implantation rate. Insufficient follow-up after AMI, which was 
demonstrated among nearly one third of the patients in the first study, could be 
one explanation. In clinical practice, many patients in Sweden have revisits to a 
cardiologist one month after AMI and since the majority are treated by means of 
revascularization it has been consider too early to discuss ICD implantation. 
Delayed decisions regarding ICD therapy after AMI are associated with a lower 
likelihood of implantation (40). 
 Other possible explanations for low implantation rates could be insufficient 
routines or referral patterns regarding patients with heart failure, individual 
physician's preferences regarding ICD therapy and safety issues of the devices, 
lack of knowledge and financial restraints. Perhaps the health-system structure in 
Sweden also influences implantation rates. Previous studies have shown that 
implanting hospitals are more likely to have cardiovascular procedure 
capabilities, are larger and more often have an academic affiliation (75). In 
Sweden, there are several small hospitals in which ICD implantations are not 
carried out and many patients with AMI or heart failure are followed up by 
doctors who are not specialized in arrhythmology.  
There are several ways to increase implantation rates. One way could be to boost 
information about the net benefit of ICD therapy among both doctors and the 
public. Another would be to decide about ICD therapy one month after 
discharge. It is also necessary, in this context, to optimize  congestive heart 
failure treatment. However, it is most important that all patients that may benefit 
from ICD treatment should be informed about both the advantages and 
disadvantages of the treatment and thereafter make an informed decision. 
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Improvement in left ventricular function after AMI 
Although the risk of SCD is highest during the first month after AMI, there are 
no benefits associated with early ICD implantation (33, 35). One explanation 
could be that many patients show improved LV function early after AMI, 
thereby diluting the positive effect. In our studies, 41–55% of patients showed 
improved LV function to such a degree that an ICD was not indicated. Recovery 
of LVEF seems to be a rapid process that starts early after AMI, and regardless 
of revascularization most patients showed improvement after one month. This 
suggests that ICD implantation may be considered after one month. 
The best situation of course would be if one could determine which patients 
would benefit from ICD treatment as early as during hospitalization for AMI. 
However, in our study there were no special features among patients who did not 
show improved LV function other than known heart failure and very impaired 
LV function. Among the 20 patients with LVEF ≤25% at inclusion, only two 
improved (LVEF 38% and 40% after three months). This implies that an ICD 
could be considered before discharge in patients with pronounced impaired LV 
function after AMI. 
In future analyses we will investigate if low-dose dobutamin stress ECHO can be 
used to pinpoint AMI patients who will show improved LV function before 
discharge. 
Efficacy of ICD treatment 
Ventricular arrhythmias are common among all patient categories with heart 
failure. In our studies both patients with and without an ICD had ventricular 
arrhythmias. In Study III, 6% of the patients annually had appropriate therapy. 
This is almost the same proportion as seen in previous well-known randomized 
ICD studies (22, 73, 76, 77). Earlier published studies have indicated that 
patients with no or many risk factors have no use of an ICD (78, 79), but we 
observed that both patients with low and high morbidity had similar rates of 
ventricular arrhythmias requiring ICD therapy, indicating that no patient should 
not be considered for an ICD implant solely on the basis of comorbidities. 
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It is of course impossible to say if the arrhythmias treated in our study by means 
of ATP or shocks would have been fatal without therapy. Many arrhythmias are 
self-terminating and modern ICD programming tries to accommodate this and 
avoid unnecessary treatment by using delayed detection algorithms (71, 80). We 
chose to report both ATPs and shocks because many clinicians program ATP 
even for very fast ventricular arrhythmias according to data from Pain Free and 
similar studies (71, 72). 
Complications 
We showed that many ICD patients (4.4% annually) suffer from device-related 
complications requiring reoperation. This is higher than in earlier randomized 
trials and almost as high as in a real-life survey carried out in Germany (57). One 
important explanation for higher complication rates in real-life surveys may be 
that in randomized studies the patients are highly selected and in our study all 
ICD patients meeting the inclusion criteria were evaluated without exception, 
thereby including patients with potentially high risks of complications. Another 
important factor is study duration. Complications increase with time. The longer 
you look, the more you find! The most frequent complications were lead-related. 
Not surprisingly, many had problems with the left-ventricular leads, but ICD-
lead complications were even more common, and the problems often appeared 
after several months. Problems with ICD leads have also been reported in other 
studies, and some types of lead show an annual failure rate of 2.6% (58).   
Another issue, which will probably continue to increase over time, is the 
occurrence of device-related infections. Multiple studies confirm increasing 
infection rates and the National Hospital Discharge Survey reported a 57% 
increase in infections but only a 12% increase in devices implanted between 
2004 and 2006 (60). The reason for the increasing infection problem is unknown, 
but multiple leads, several surgical procedures, generator replacement, pocket 
hematoma and a high level of morbidity are factors that are correlated to higher 
infection rates (81). Perhaps more antibiotic use and increased bacterial 
resistance in the community also contribute to the higher infection rates seen 
today. 
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Complications are resource-demanding and even in low absolute numbers they 
have an impact on the net health-economic benefit of treatment, and the quality 
of life of affected patients. However, no complications in our study were lethal 
and there was no association between complications and increased mortality. 
Shocks  
Shocks from ICDs can have a traumatic impact on the patient, causing stress, 
great pain and anxiety. Repeated shocks have been shown to have a particularly 
negative impact on the quality of life of ICD patients, causing considerable 
emotional distress (82, 83). 
 In our study only 7% of patients (2.4% annually) had unnecessary shocks, a 
figure slightly lower than in many other studies, in which the occurrence of 
inappropriate shocks has ranged from 10% to 24% over 20 to 45 months of 
follow-up (84, 85). The main reason for inappropriate therapy in our study, as in 
several others, was atrial fibrillation. Better knowledge and more “conservative” 
programming (i.e. higher VT zones with longer detection intervals and more 
ATP therapy attempts before shock therapy) may have contributed to the 
reduced number of unnecessary shocks. Use of newer or improved 
discriminatory features such as continually updated morphology templates may 
also have improved correct arrhythmia classification. 
Even correct shock treatment is painful and causes stress if the patients are 
awake. In our study we showed that 31% of the ICD patients had shocks at the 
end of life. Many patients had shock treatment programmed ON even if they had 
a DNR order. This highlights the need to address the problem of ICD shocks 
during the end-of-life period and to improve knowledge about ICDs among other 
professions in palliative care units. It is also necessary to discuss device 
deactivation with patients and their families when the end of life approaches. 
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Deaths 
Patients with heart failure after AMI have a high mortality rate. We showed that 
mortality increased distinctly with morbidity, but there were no gender 
differences. We found no association between death and inappropriate shocks or 
complications requiring reoperation. 
The most common cause of death among ICD patients was heart failure, 
especially among patients with a high level of morbidity. Another common 
cause of death was malignancy, but even patients with ICDs sometimes died of 
arrhythmia. Since devices seldom are explanted after death the true numbers of 
cases of arrhythmia and device malfunction are not known. In our study of 
explanted ICDs, four had signs of device malfunction and in Study IIII we 
showed that the devices were seldom interrogated after death. 
 Many patients with an ICD (21%) had previous arrhythmia appropriately treated 
by ATP and/or shocks before death, but neither previous shock nor ATP therapy 
were associated with death during follow-up. The median time from first 
correctly treated arrhythmia to time of death was 16 months (range 0.5–47 
months) and perhaps the ICD prolonged their lives. Neither appropriate nor 
inappropriate therapy were correlated to death in our study. This contradicts the 
results of earlier published studies which have reported an association between 
shock therapy and death (68, 84). 
Patients with a high level of morbidity have a high mortality rate in spite of ICD 
therapy, but ICD treatment may extend their lives. It is important to identify 
these patients before implantation and give them correct information regarding 
realistic assessment of the expected benefit of ICD therapy. It is possible that 
some patients will choose not to undergo ICD therapy, or prefer a CRT 
pacemaker instead of a CRT defibrillator. 
Gender differences 
In all our studies, as in many other studies regarding ICD therapy, there were 
significantly fewer women than men. One explanation could be that women have 
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a lower incidence of coronary heart diseases and are older when they become ill. 
Even so, the question remains – are women offered the treatment to the same 
extent as men? In the national Swedish registry for coronary heart disease, the 
incidence of AMI is consistently about 50% lower per age group in women 
compared with men, but this does not explain the fact that only 18% of primary 
prophylactic ICD recipients are women (1). 
Another question is – do women have equal benefit from ICD treatment? We 
observed that women had a significantly lower rate of correctly treated 
arrhythmia episodes (9% compared with 20% in men), but the mortality rate was 
the same. Earlier published meta-analyses of gender differences in primary 
preventive ICD treatment have also shown that women have a significantly 
lower rate of appropriate therapies and fewer survival benefits (86). Perhaps men 
have a greater propensity for ventricular arrhythmia and a higher rate of sudden 
cardiac death (87). There is a need for prospective studies including all 
implanted patients (“real- world” cohorts) in order to clarify this issue. 
Real-life cohort  
All papers in this thesis are based on real-life data and not controlled randomized 
studies. The cohorts in Paper III were based on consecutive patients from four 
large hospitals in Sweden, representing almost 30% of the yearly ICD implants 
in the country, which supports the ability to generalize the study findings. Since 
all patients in the hospital catchment areas who actually received ICD treatment 
were included, the findings are more likely to represent the “true” net result of 
primary prophylactic ICD treatment, as compared with selected patient cohorts 
in prospective randomized trial populations. In most randomized studies, patients 
with high-level morbidity, advanced age or previous infarction are excluded. 
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7 CONCLUSIONS 
• Compliance to guidelines regarding primary preventive defibrillators 
needs to be improved. Many patients are not offered treatment even if 
they fulfill criteria for ICD therapy.  
• Many patients show significantly improved LV function after AMI to 
such an extent that an indication for ICD implantation is no longer 
present. This may be one explanation for why early ICD implantation 
after AMI has failed to show survival benefit.  
• Improvement of LV function after AMI is a rapid process regardless of 
revascularization. Most patients show improved LV function after one 
month and further improvement up to three months is minor. This 
indicates that we can offer ICD treatment to patients at risk at an earlier 
stage.  
• Many patients, 6% annually, with a primary preventive ICD because of 
congestive heart failure have correctly treated ventricular arrhythmias 
and thereby benefit from the treatment.  
• Complications of ICD therapy are common during long-term follow-up. 
Complications requiring reoperation occurred annually in 4.4% of cases, 
and inappropriate shocks in 2.4%. Complications were not associated 
with increased mortality.  
• Men were twice as likely to receive ICD therapy compared with women, 
but neither total mortality nor complication rates differed significantly. 
• More than a third of the ICD patients studied had ventricular 
tachyarrhythmia within the last hour of life. Devices remained active in 
more than half of the patients with a do-not-resuscitate order. Increased 
knowledge about ICD treatment is nescessary among healthcare 
professionals.   
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8 FUTURE PERSPECTIVES 
Decisions concerning ICD implantation as early as one month after AMI will 
probably increase implantation rates in Sweden. It is to be hoped that future 
analyses of the results of dobutamin stress ECHO will answer the question of 
whether or not it is possible to determine if LV function will improve before 
discharge after AMI, thereby allowing ICD implantation even earlier than one 
month after infarction. Further echocardiographic analyses after six and twelve 
months will give us information regarding what happens among patients with 
LVEF slightly > 35% in a longer perspective. We also hope that analyses of 
Holter registrations, blood samples and other parameters will help to pinpoint 
patients at the highest risk of SCD. 
It is important to increase knowledge of ICD therapy both in society and, more 
particularly, among professionals in palliative care units.  
There is a need of more studies to investigate the net benefit of ICD therapy 
among women with congestive heart failure.   
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9 SVENSK SAMMANFATTNING 
Varje år drabbas 8 000-10000 personer i Sverige av plötslig hjärtdöd. Högst risk 
för plötslig död har patienter med tidigare hjärtinfarkt och hjärtsvikt. Ett flertal 
studier har visat att förebyggande behandling med inopererad defibrillator (ICD) 
markant minskar dödligheten hos patienter med nedsatt hjärtfunktion oavsett om 
den är orsakad av en hjärtinfarkt eller inte. Trots att risken för plötslig död är 
som störst första månaden efter en hjärtinfarkt har ICD behandling under denna 
tidsperiod inte visat ökat överlevnad. Både svenska och internationella riktlinjer 
förordar förebyggande behandling med inopererad defibrillator (ICD) till 
patienter med bestående hjärtsvikt och minst måttligt nedsatt pumpkraft tidigast 
40 dagar efter en hjärtinfarkt och man bör vänta i 3 månader om patienten 
behandlats med en kranskärlsoperation eller ballongvidgning av hjärtat blodkärl. 
I  studie 1 undersöktes hur vi följer riktlinjerna avseende ICD behandling till 
patienter med hjärtsvikt efter en hjärtinfarkt och hur vanligt det är att hjärtat 
återhämtar sig efter en hjärtinfarkt. Vi undersökte de medicinska journalerna från 
187 patienter med hjärtinfarkt som vid utskrivningen från sjukhus hade minst 
måttligt nedsatt pumpkraft i hjärtat. Vi fann att 32 % av patienterna inte fick 
korrekt uppföljning där man tog ställning till ICD behandling och att 41 % 
förbättrade sin hjärtfunktion till en sådan grad att de inte längre hade nytta av 
ICD behandling. 
I studie 2, undersökte vi dels andelen patienter som förbättrade sin hjärtfunktion 
efter en hjärtinfarkt och dels hur lång tid förbättringen tog. Vi inkluderade 100 
patienter med akut hjärtinfarkt och hjärtsvikt i studien och utförde upprepade 
ultraljudsundersökningar efter fem dagar, en och tre månader efter infarkten. Vi 
fann att redan efter en månad hade 55 % av patienterna förbättrat sin 
hjärtfunktion i sådan omfattning att ICD behandling inte var aktuellt, detta trots 
att merparten behandlats med ballongvidgning av hjärtats kranskärl. Fortsatt 
förbättring av hjärtfunktionen skedde, men i liten omfattning, talande för att 
beslut om ICD kan tas redan 1 månad efter hjärtinfarkten. Vi fann också att 9 % 
drabbades av livshotande rytmrubbningar de första veckorna efter hjärtinfarkten 
vilket poängterar den stora risken för plötslig död kort tid efter en hjärtinfarkt. 
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I studie 3 undersökte vi nyttan och komplikationsrisken med ICD behandling. 
Vi analyserade medicinska journalerna från 865 patienter som fått förebyggande 
behandling med ICD på grund av hjärtsvikt. Vi fann att 6 % av patienterna 
årligen fick korrekt behandling för livshotande arytmier, men kvinnorna i studien 
hade bara hälften så mycket arytmier som männen. Den årliga risken för 
komplikationer var 6.8% och av dessa var 4.4% komplikationer som krävde ny 
operation och 2.4% felaktiga chocker. 
I studie 4 analyserade vi vad som skedde med ICD behandlande patienter det 
sista dygnet i livet. Vi samlade in 125 ICD doser från avlidna patienter. Vi fann 
att många patienter drabbades av både rytmrubbningar (38 %) och chock 
behandling (31 %) det sista dygnet i livet. Trots att man i många fall tagit 
ställning till att återupplivning inte var aktuell hade man inte inaktiverat 
defibrillatorns chock-behandling.  
Sammanfattningsvis visade studierna att uppföljningen efter hjärtinfarkt är 
bristfällig. Förbättring av hjärtfunktionen efter en hjärtinfarkt sker hos många 
och den har hos flertalet patienter redan inträffat efter 1 månad, talande för att vi 
inte behöver vänta längre med ICD behandling. Hjärtsviktspatienter, speciellt 
män, har nytta av ICD behandling men komplikationer är vanliga och det är 
viktigt att inaktivera ICD behandlingen i livets slutskede.  
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